ID   R144B_HUMAN             Reviewed;         303 AA.
AC   Q7Z419; B3KUA8; B4DZI2; Q5TB85; Q6P4Q0; Q8N3R7; Q9BX38;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2003, sequence version 1.
DT   07-APR-2021, entry version 153.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF144B;
DE            EC=2.3.2.31 {ECO:0000250|UniProtKB:O60260};
DE   AltName: Full=IBR domain-containing protein 2;
DE   AltName: Full=RING finger protein 144B;
DE   AltName: Full=p53-inducible RING finger protein;
GN   Name=RNF144B; Synonyms=IBRDC2, P53RFP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND INTERACTION WITH
RP   LCMT2.
RX   PubMed=12853982; DOI=10.1038/sj.onc.1206586;
RA   Ng C.-C., Arakawa H., Fukuda S., Kondoh H., Nakamura Y.;
RT   "p53RFP, a p53-inducible RING-finger protein, regulates the stability of
RT   p21WAF1.";
RL   Oncogene 22:4449-4458(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Prostate, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skeletal muscle;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND INTERACTION WITH UBE2L3 AND UBE2L6.
RX   PubMed=16427630; DOI=10.1016/j.febslet.2005.09.105;
RA   Huang J., Xu L.-G., Liu T., Zhai Z., Shu H.-B.;
RT   "The p53-inducible E3 ubiquitin ligase p53RFP induces p53-dependent
RT   apoptosis.";
RL   FEBS Lett. 580:940-947(2006).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH
RP   BAX.
RX   PubMed=20300062; DOI=10.1038/emboj.2010.39;
RA   Benard G., Neutzner A., Peng G., Wang C., Livak F., Youle R.J.,
RA   Karbowski M.;
RT   "IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax
RT   and apoptosis activation.";
RL   EMBO J. 29:1458-1471(2010).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from E2
CC       ubiquitin-conjugating enzymes UBE2L3 and UBE2L6 in the form of a
CC       thioester and then directly transfers the ubiquitin to targeted
CC       substrates such as LCMT2, thereby promoting their degradation. Induces
CC       apoptosis via a p53/TP53-dependent but caspase-independent mechanism.
CC       However, its overexpression also produces a decrease of the ubiquitin-
CC       dependent stability of BAX, a pro-apoptotic protein, ultimately leading
CC       to protection of cell death; But, it is not an anti-apoptotic protein
CC       per se. {ECO:0000269|PubMed:12853982, ECO:0000269|PubMed:20300062}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[E2 ubiquitin-conjugating enzyme]-S-ubiquitinyl-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + [acceptor protein]-N(6)-ubiquitinyl-L-lysine.;
CC         EC=2.3.2.31; Evidence={ECO:0000250|UniProtKB:O60260};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with UBE2L3, UBE2L6 and LCMT2, as well as with BAX.
CC       {ECO:0000269|PubMed:12853982, ECO:0000269|PubMed:16427630,
CC       ECO:0000269|PubMed:20300062}.
CC   -!- INTERACTION:
CC       Q7Z419; Q07812: BAX; NbExp=5; IntAct=EBI-2129982, EBI-516580;
CC       Q7Z419; O15350: TP73; NbExp=2; IntAct=EBI-2129982, EBI-389606;
CC       Q7Z419; O15350-8: TP73; NbExp=2; IntAct=EBI-2129982, EBI-5651259;
CC       Q7Z419; O14933: UBE2L6; NbExp=4; IntAct=EBI-2129982, EBI-2129974;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion membrane
CC       {ECO:0000269|PubMed:20300062}; Single-pass membrane protein
CC       {ECO:0000269|PubMed:20300062}. Cytoplasm {ECO:0000269|PubMed:20300062}.
CC       Note=Mostly cytosololic, accumulates in submitochondrial domains
CC       specifically upon apoptosis induction, in synchrony with BAX
CC       activation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q7Z419-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q7Z419-2; Sequence=VSP_055853, VSP_055854;
CC   -!- TISSUE SPECIFICITY: Broadly expressed, with lowest levels in brain and
CC       thymus, and highest levels detectable in heart, ovary and testis.
CC       {ECO:0000269|PubMed:16427630, ECO:0000269|PubMed:20300062}.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme (By similarity). The transmembrane domain
CC       is essential for translocation to the mitochondria upon induction of
CC       apoptosis. {ECO:0000250}.
CC   -!- DOMAIN: Members of the RBR family are atypical E3 ligases. They
CC       interact with the E2 conjugating enzyme UBE2L3 and function like HECT-
CC       type E3 enzymes: they bind E2s via the first RING domain, but require
CC       an obligate trans-thiolation step during the ubiquitin transfer,
CC       requiring a conserved cysteine residue in the second RING domain.
CC       {ECO:0000250|UniProtKB:O60260}.
CC   -!- PTM: Auto-ubiquitinated.
CC   -!- SIMILARITY: Belongs to the RBR family. RNF144 subfamily. {ECO:0000305}.
CC   -!- CAUTION: Lacks the His residue in the RING-type domain 2 that is one of
CC       the conserved features of the family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD38622.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB076367; BAC02434.1; -; mRNA.
DR   EMBL; AK096832; BAG53370.1; -; mRNA.
DR   EMBL; AK302935; BAG64094.1; -; mRNA.
DR   EMBL; AL832329; CAD38622.1; ALT_INIT; mRNA.
DR   EMBL; AL138725; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471087; EAW55407.1; -; Genomic_DNA.
DR   EMBL; BC063311; AAH63311.1; -; mRNA.
DR   CCDS; CCDS34345.1; -. [Q7Z419-1]
DR   RefSeq; NP_877434.2; NM_182757.3. [Q7Z419-1]
DR   BioGRID; 129106; 37.
DR   DIP; DIP-43771N; -.
DR   IntAct; Q7Z419; 11.
DR   MINT; Q7Z419; -.
DR   STRING; 9606.ENSP00000259939; -.
DR   iPTMnet; Q7Z419; -.
DR   PhosphoSitePlus; Q7Z419; -.
DR   BioMuta; RNF144B; -.
DR   DMDM; 57012811; -.
DR   MassIVE; Q7Z419; -.
DR   PaxDb; Q7Z419; -.
DR   PeptideAtlas; Q7Z419; -.
DR   PRIDE; Q7Z419; -.
DR   ProteomicsDB; 5602; -.
DR   ProteomicsDB; 69130; -. [Q7Z419-1]
DR   Antibodypedia; 2130; 392 antibodies.
DR   DNASU; 255488; -.
DR   Ensembl; ENST00000259939; ENSP00000259939; ENSG00000137393. [Q7Z419-1]
DR   GeneID; 255488; -.
DR   KEGG; hsa:255488; -.
DR   UCSC; uc003ncs.3; human. [Q7Z419-1]
DR   CTD; 255488; -.
DR   DisGeNET; 255488; -.
DR   GeneCards; RNF144B; -.
DR   HGNC; HGNC:21578; RNF144B.
DR   HPA; ENSG00000137393; Low tissue specificity.
DR   MIM; 618869; gene.
DR   neXtProt; NX_Q7Z419; -.
DR   OpenTargets; ENSG00000137393; -.
DR   PharmGKB; PA162401565; -.
DR   VEuPathDB; HostDB:ENSG00000137393.9; -.
DR   eggNOG; KOG1815; Eukaryota.
DR   GeneTree; ENSGT00940000158819; -.
DR   HOGENOM; CLU_053598_1_0_1; -.
DR   InParanoid; Q7Z419; -.
DR   OMA; DCQTVCH; -.
DR   OrthoDB; 1188714at2759; -.
DR   PhylomeDB; Q7Z419; -.
DR   TreeFam; TF324777; -.
DR   PathwayCommons; Q7Z419; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 255488; 29 hits in 990 CRISPR screens.
DR   ChiTaRS; RNF144B; human.
DR   GenomeRNAi; 255488; -.
DR   Pharos; Q7Z419; Tbio.
DR   PRO; PR:Q7Z419; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q7Z419; protein.
DR   Bgee; ENSG00000137393; Expressed in quadriceps femoris and 216 other tissues.
DR   Genevisible; Q7Z419; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031966; C:mitochondrial membrane; IDA:UniProtKB.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IBA:GO_Central.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0000209; P:protein polyubiquitination; IBA:GO_Central.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR031127; E3_UB_ligase_RBR.
DR   InterPro; IPR002867; IBR_dom.
DR   InterPro; IPR044066; TRIAD_supradom.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR11685; PTHR11685; 1.
DR   Pfam; PF01485; IBR; 2.
DR   SMART; SM00647; IBR; 2.
DR   SMART; SM00184; RING; 2.
DR   PROSITE; PS51873; TRIAD; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; Cytoplasm; Membrane; Metal-binding;
KW   Mitochondrion; Reference proteome; Repeat; Transferase; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..303
FT                   /note="E3 ubiquitin-protein ligase RNF144B"
FT                   /id="PRO_0000055911"
FT   TRANSMEM        258..278
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   ZN_FING         30..80
FT                   /note="RING-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   ZN_FING         101..166
FT                   /note="IBR-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   ZN_FING         193..222
FT                   /note="RING-type 2; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   REGION          26..244
FT                   /note="TRIAD supradomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   ACT_SITE        206
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           30
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           33
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           53
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           56
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           121
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           126
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           145
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           148
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           153
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           156
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           161
FT                   /note="Zinc 3; via tele nitrogen"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           166
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           193
FT                   /note="Zinc 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           196
FT                   /note="Zinc 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           211
FT                   /note="Zinc 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           214
FT                   /note="Zinc 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           219
FT                   /note="Zinc 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           222
FT                   /note="Zinc 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           234
FT                   /note="Zinc 5; via tele nitrogen"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   METAL           240
FT                   /note="Zinc 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   VAR_SEQ         1..21
FT                   /note="MGSAGRLHYLAMTAENPTPGD -> MLWITMPHPAHLGLFIAVTLS (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055853"
FT   VAR_SEQ         22..110
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055854"
FT   CONFLICT        262
FT                   /note="L -> P (in Ref. 3; CAD38622)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        275
FT                   /note="Missing (in Ref. 6; AAH63311)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   303 AA;  33697 MW;  9FD505CDFB70B6A5 CRC64;
     MGSAGRLHYL AMTAENPTPG DLAPAPLITC KLCLCEQSLD KMTTLQECQC IFCTACLKQY
     MQLAIREGCG SPITCPDMVC LNHGTLQEAE IACLVPVDQF QLYQRLKFER EVHLDPYRTW
     CPVADCQTVC PVASSDPGQP VLVECPSCHL KFCSCCKDAW HAEVSCRDSQ PIVLPTEHRA
     LFGTDAEAPI KQCPVCRVYI ERNEGCAQMM CKNCKHTFCW YCLQNLDNDI FLRHYDKGPC
     RNKLGHSRAS VMWNRTQVVG ILVGLGIIAL VTSPLLLLAS PCIICCVCKS CRGKKKKHDP
     STT
//
